Gentium (GENT) Amends Defibrotide Development and Commercialization Agreement for the Americas with Sigma-Tau Pharma
Tweet Send to a Friend
Gentium S.p.A. (NASDAQ: GENT) today announced that it has amended its existing License and Supply and Cost Sharing Agreements with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
